"We keep our PFE target price of $33.... The
split-off came earlier than we expected, probably reflecting the present strong
general market and IPO environment. We expect the split to be accretive to EPS
next year, as retirement of the exchanged PFE shares results in fewer shares.
The split-off also allows PFE greater focus on its core higher-margin drug
business. The dividend yields 3.2%. "
Yeah, Sam Stovall runs that outfit (S&P Capital IQ / Capital Equity). I trust him; I don't think that there is any high-jinx there. Everytime which I have heard him speak (on PBS or Ameritrade) he's seems honest and extremely knowledgeable regarding his topics; he also seems ethical. In short, a stand up guy.
S&P's recommendation is part of why I am here on PFE.